12 October 2016AmericasSandra Kuzmich and Russell Garman
Life Technologies v Promega: the long tentacles of infringement
After hearing three patent cases in its last term, the US Supreme Court agreed in June to take on another: Life Technologies et al v Promega et al. The Supreme Court’s focus will be on the meaning of a particular phrase—“substantial portion”—that appears in 35 USC §271(f)(1). This section of the patent statute governs infringement in circumstances where components from the US are shipped abroad for inclusion in a combination that would have infringed a patent had the combination been manufactured in the US.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.
22 December 2025 Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.
17 December 2025 The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the pharmaceutical industry, but for all stakeholders in our patent system”.